CME MULTIMEDIA ACTIVITIES

March 2015
Anticoagulation in the Emergency Department: A Case-Based Approach to Managing Patients with Venous Thromboembolism and Nonvalvular Atrial Fibrillation

Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP (Chair), Elaine Hylek, MD, MPH, David E. Slattery, MD, FACEP, FAAEM

This activity has been designed to address the educational needs of emergency medicine physicians and other clinicians who work in the emergency department who are involved in anticoagulation management.

Commercial Support:  This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Review and Sponsorship:  This activity was peer reviewed by The Journal of Emergency Medicine, and is provided by Global Education Group. Paradigm Medical Communications, LLC is the educational partner.

December 2013
Community-Acquired Bacterial Pneumonia: The Emergency Department as a Pivotal Point of Care

Presenters:  Gregory Moran, MD, FACEP, Charles V. Pollack, Jr., MA, MD, FACEP

During this interactive enduring CME activity, Emergency Department specialists will discuss common challenges of managing patients with community-acquired bacterial pneumonia (CABP), including the integration of newer agents into the standard anti-infective mix. Decisions made at this pivotal point of care can affect both patient outcomes and hospital financial health. "Real-world" cases will be used to demonstrate strategies for stratifying risk according to severity; recognizing risk factors for multidrug-resistant CABP; discerning indications for hospital admission; and initiating early and appropriate antibiotic treatment within the parameters of clinical guidelines, evolving performance measures, and sound clinical judgment.

Commercial Support:  This activity is supported by an educational grant from Forest Laboratories, Inc.

Review and Sponsorship:  This interactive web monograph was peer reviewed by The Journal of Emergency Medicine, and is sponsored by Paradigm Medical Communications, LLC.

December 2013
CaseBook Challenges: Initiating Antiplatelet Therapy for ACS Patients in the Emergency Department - Dialogue with the Experts

Presenters:  Deborah B. Diercks, MD, MSc; Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA; Matthew J. Price, MD, FACC, FSCAI

In the United States, about 8% to 10% of the 119 million annual visits to emergency departments (EDs) are for chest pain and other symptoms consistent with acute coronary syndrome (ACS). Accurate and rapid assessment of the risk for adverse, life-threatening coronary events in these individuals is critical and represents a challenge for ED clinicians. Once diagnosed, guidelines recommend early initiation of dual antiplatelet therapy with aspirin plus a P2Y₁₂ inhibitor, traditionally clopidogrel, for all ACS patients regardless of whether a conservative or invasive approach will be used downstream. Therefore, to appropriately triage patients, ED clinicians must have an understanding of the different pharmacodynamic, efficacy, and safety profiles of the available antiplatelet therapies, and be familiar with the recently updated ACS guidelines pertinent to the management of these patients.

This case-based symposium will use an interactive format to provide ED clinicians with an opportunity for expert faculty dialogue concerning the clinical implications of risk stratification tools; different efficacy and safety profiles of the P2Y₁₂ inhibitors, including balancing the risk of thrombosis versus bleeding events; interpatient variability in response to antiplatelet therapy; and guideline recommendations for antiplatelet therapy in patients with ACS.

Commercial Support:  This activity is supported by an educational grant from AstraZeneca LP.

Review and Sponsorship:  This CME Multimedia Activity has been peer-reviewed by The Journal of Emergency Medicine, and The Journal for Nurse Practitioners, and is jointly sponsored by Continuum Health Partners, Inc.(Beth Israel University Hospital and Manhattan Campus for the Albert Einstein College of Medicine, St. Luke's Roosevelt University Hospital of Columbia University College of Physicians and Surgeons) and Health Education Alliance.

April 2013
CaseBook Challenges: Managing Gout, Hyperuricemia and Comorbidities - Dialogue with the Experts
(iPad compatible)

Presenters: George L. Bakris, MD, FASH, FASN, Paul P. Doghramji, MD, FAAFP, Robert T. Keenan, MD, MPH, Steven H. Silber, DO, FACEP

As the prevalence of gout continues to increase in the United States, primary care and emergency department clinicians can expect to see more patients who present with the symptoms and complications of this disease. In addition to treating and preventing acute flares and halting disease progression, clinical strategies for the management of gout and hyperuricemia must include considerations for common renal and cardiometabolic conditions, including hypertension and diabetes, which are associated with elevated serum urate levels. Utilizing patient video cases, this CME/CE program provides expert discussion of the everyday challenges clinicians face in diagnosing and treating gout, including key steps in making a presumptive diagnosis, the rationale and sequencing of pharmacotherapy for acute and chronic gout, the importance of reaching target serum urate level, and communicating with patients to improve both their understanding of the disease process and their adherence to long-term treatment.

Commercial Support:  This activity is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

Review and Sponsorship:  This multimedia activity was peer reviewed by The Journal of Emergency Medicine, The Journal for Nurse Practitioners and The American Journal of Medicine, and is jointly sponsored by Elsevier Office of Continuing Medical Education and Health Education Alliance, Inc.
 

December 2012
CaseBook Challenges: Individualizing Antiplatelet Therapy in the Emergency Department - Dialogue with the Experts

Presenters: Marc Cohen, MD, FACC, James Hoekstra, MD, FACEP, Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA

After initial evaluation and risk stratification, depending on diagnosis, patients who suffer ACS may be treated medically, by percutaneous coronary intervention (PCI), or surgically. The availability of novel antiplatelet therapies requires that ED clinicians be familiar with comparative safety and efficacy data, revisions to pertinent guidelines, and the potential role of the new therapies.

Utilizing an audience interactive format, this case-based activity provides an opportunity for expert faculty dialogue/commentary, and addresses the clinical implications of current guidelines for use of antiplatelet therapy in ACS patients, platelet function testing and/or genotyping, risk stratification tools, novel antiplatelet therapies, and strategies that balance efficacy and bleeding risk in relation to decision making in the emergency department.

Commercial Support:  This activity is supported by an educational grant from AstraZeneca LP.

Review and Sponsorship:  This multimedia activity was peer reviewed by The Journal of Emergency Medicine and The Journal for Nurse Practitioners, and jointly sponsored by Beth Israel Medical Center & St. Luke’s and Roosevelt Hospitals and Health Education Alliance, Inc.